| Literature DB >> 29631866 |
Rocío Aller1, Conrado Fernández-Rodríguez2, Oreste Lo Iacono3, Rafael Bañares4, Javier Abad5, José Antonio Carrión6, Carmelo García-Monzón7, Joan Caballería8, Marina Berenguer9, Manuel Rodríguez-Perálvarez10, José López Miranda10, Eduardo Vilar-Gómez11, Javier Crespo12, Miren García-Cortés13, María Reig8, José María Navarro14, Rocío Gallego11, Joan Genescà15, María Teresa Arias-Loste12, María Jesús Pareja16, Agustín Albillos17, Jordi Muntané18, Francisco Jorquera19, Elsa Solà8, Manuel Hernández-Guerra20, Miguel Ángel Rojo1, Javier Salmerón21, Llorenc Caballería22, Moisés Diago23, Esther Molina24, Ramón Bataller25, Manuel Romero-Gómez26.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the main cause of liver diseases in Spain and the incidence is raising due to the outbreak of type 2 diabetes and obesity. This CPG suggests recommendation about diagnosis, mainly non-invasive biomarkers, and clinical management of this entity. Life-style modifications to achieve weight loss is the main target in the management of NAFLD. Low caloric Mediterranean diet and 200 minutes/week of aerobic exercise are encouraged. In non-responders patients with morbid obesity, bariatric surgery or metabolic endoscopy could be indicated. Pharmacological therapy is indicated in patients with NASH and fibrosis and non-responders to weight loss measures. NAFLD could influence liver transplantation, as a growing indication, the impact of steatosis in the graft viability, de novo NAFLD rate after OLT and a raised cardiovascular risk that modify the management of this entity. The current CPG was the result of the First Spanish NAFLD meeting in Seville.Entities:
Keywords: Cardiovascular risk; Clinical guidelines; Diagnosis; Diagnóstico; Enfermedad por hígado graso no alcohólico; Esteatosis; Fibrosis; Guías clínicas; Non-alcoholic fatty liver disease; Recomendaciones; Recommendations; Riesgo cardiovascular; Steatosis; Tratamiento; Treatment
Mesh：
Year: 2018 PMID： 29631866 DOI： 10.1016/j.gastrohep.2017.12.003
Source DB: PubMed Journal: Gastroenterol Hepatol ISSN： 0210-5705 Impact factor: 2.102